{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7"},{"groupId":"OG001","value":"42.9"}]}],"title":"Serotype 1-146 (1)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5"},{"groupId":"OG001","value":"28.6"}]}],"title":"Serotype 3-146 (3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7"},{"groupId":"OG001","value":"60.7"}]}],"title":"Serotype 4-146 (4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1"},{"groupId":"OG001","value":"60.7"}]}],"title":"Serotype 6/26-146 (6B)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"57.1"}]}],"title":"Serotype 8-146 (8)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"60.7"}]}],"title":"Serotype 9-146 (9N)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"50.0"}]}],"title":"Serotype 12-146 (12F)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2"},{"groupId":"OG001","value":"60.7"}]}],"title":"Serotype 14-146 (14)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4"},{"groupId":"OG001","value":"53.6"}]}],"title":"Serotype 19-146 (19F)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6"},{"groupId":"OG001","value":"35.7"}]}],"title":"Serotype 23-146 (23F)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4"},{"groupId":"OG001","value":"60.7"}]}],"title":"Serotype 51-146 (7F)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6"},{"groupId":"OG001","value":"57.1"}]}],"title":"Serotype 56-146 (18C)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"The immune response to each of the 12 anti-pneumococcal antibody serotypes was measured in serum samples immediately prior to and 4 weeks after vaccine administration. The pneumococcal antibody assay was a fluoroimmunoassay that used a Luminex Multiplex platform. Purified capsular polysaccharides isolated from 12 serotypes of S. pneumonia were covalently attached to microbeads and used as a capturing reagent. Phycoerythrin conjugated anti-human IgG was used for detection. A positive immune response against a serotype was defined as a 2-fold increase or an increase of \\> 1 μg/mL from pre-vaccination levels.","groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG001","title":"Methotrexate (Group B)"}],"paramType":"NUMBER","populationDescription":"Immune response per-protocol population: Group A - All patients randomized to Group A who received any rituximab infusion and any vaccine and had pre-vaccination and 4-week post-vaccination blood samples. Group B - All patients randomized to Group B who received any vaccine and had pre-vaccination and 4-week post-vaccination blood samples.","reportingStatus":"POSTED","timeFrame":"Week 28 to Week 32 for Group A and Week 4 to Week 8 for Group B","title":"Percentage of Patients With a Positive Immune Response to Each of the 12 Anti-pneumococcal Antibody Serotypes in Response to the 23-valent Pneumococcal Polysaccharide Vaccine","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}